NEW YORK (GenomeWeb News) – Trovagene this week filed a shelf registration with the US Securities and Exchange Commission for the public offering of up to $150 million in securities from time to time.
A spokesperson for the San Diego-based molecular diagnostic firm said the filing is associated with a public offering that the company made in the spring of 2012 when it began trading its stock on the Nasdaq.
Proceeds from any offering associated with this week's filing will go toward general corporate purposes, including working capital, R&D, clinical trial expenses, regulatory efforts, and acquisitions, the company said.
Trovagene separately also said in another SEC document that it has entered into a controlled equity offering sales agreement with Cantor Fitzgerald to offer and sell up to $30 million of its stock through the investment bank.